Trial Profile
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2015
Price :
$35
*
At a glance
- Drugs Prezalumab (Primary) ; Prezalumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Amgen
- 20 Mar 2015 New trial record